IPO Year: 2023
Exchange: NASDAQ
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
3 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
3 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.34) per share. This is a 12.82 percent increase over losses of $(0.39) per share from the same period last year.
- SEC Filing
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primarily due to the completion of enrollment in the IT-01 study in mid-2022. This decrease was partially offset by higher 2023 expenses for start-up work on the INVINCIBLE-3 study and a new manufacturing batch of INT230-6.General and administrative expenses were $3.5 million for the year ended December 31, 2023, compared to $2.4 million for the same period in 2022. The increase was primarily due to salary and bonus increases, including the hiring of a new chief financial officer in the fourth quarter
SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)
SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)
8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
10-Q - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
EFFECT - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
EFFECT - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
S-8 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
S-3 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
S-3 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
DEFA14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas
Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than
SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcomaCollaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in EuropeCash and investments of $6.3 million expected to fund operations into the first quarter of 2025SHELTON, Conn., Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announ
Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy SHELTON, Conn., July 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, announces that the first U.S. patient has been dosed in the Company's Phase 3 study to treat metastatic sarcoma (NCT06263231). The trial is a superiority study testing INT230-6 as monothera
SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas
SHELTON, Conn., May 10, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, (one to one), controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care ("SOC") immuno/chemotherapy vs. SOC immune/chemotherapy alone in
INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancerCash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025SHELTON, Conn., May 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2024 financial results and provides a corporate update.
SHELTON, Conn., April 2, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024. The conference is being held on April 8 - 9, 2024 at the Sofitel Hotel in New York City. Presentation Date: Tuesday
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ:INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monetize its equity holdings in INTS and bring in proceeds, net of related expenses, totaling $2.8M of non-dilutive funding. The Company will use the proceeds to further fund its PORT-6 Phase 1a portion of the ADPORT-601 trial. "The Company looks forward to submitting interim data from
INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancerYear-end cash and investments of $14.8 million expected to fund operations through the end of Q1 '25Focusing on clinical operational and regulatory progress for a new technology to treat cancerMultiple clinical opportunities in cancer types having high unmet medical needUpcoming clinical milestonesSHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kil
SHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will participate in a fireside chat with Roth Managing Director and Senior Analyst, Jonathan Aschoff, Ph.D. at the 36th Annual Roth Conference in Orange County, CA on Tuesday, March 19, at 12:30PM PDT at the Ritz Carlton in Laguana Nigel, CA in the Healthcare Suite 2022.